Bristol Myers Squibb Company (NYSE:BMY) Shares Purchased by Diversified Trust Co

Diversified Trust Co lifted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 20.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 55,658 shares of the biopharmaceutical company's stock after acquiring an additional 9,503 shares during the quarter. Diversified Trust Co's holdings in Bristol Myers Squibb were worth $3,395,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Bedel Financial Consulting Inc. boosted its position in Bristol Myers Squibb by 3.2% in the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock valued at $340,000 after buying an additional 175 shares during the last quarter. King Wealth Management Group boosted its position in Bristol Myers Squibb by 2.6% in the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock valued at $413,000 after buying an additional 182 shares during the last quarter. Thoroughbred Financial Services LLC boosted its position in Bristol Myers Squibb by 1.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock valued at $1,004,000 after buying an additional 190 shares during the last quarter. Marcum Wealth LLC boosted its position in Bristol Myers Squibb by 1.0% in the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock valued at $1,177,000 after buying an additional 193 shares during the last quarter. Finally, Chatham Capital Group Inc. boosted its position in Bristol Myers Squibb by 0.9% in the 4th quarter. Chatham Capital Group Inc. now owns 21,795 shares of the biopharmaceutical company's stock valued at $1,233,000 after buying an additional 200 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

BMY opened at $46.34 on Friday. The firm has a market cap of $94.31 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 1.38 and a beta of 0.38. Bristol Myers Squibb Company has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company's 50-day moving average price is $47.90 and its 200 day moving average price is $53.94. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the business earned ($4.40) earnings per share. Bristol Myers Squibb's revenue was down 5.6% compared to the same quarter last year. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.35%. Bristol Myers Squibb's payout ratio is currently 92.88%.

Analyst Ratings Changes

BMY has been the subject of a number of analyst reports. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Finally, Piper Sandler began coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has a consensus rating of "Hold" and an average target price of $58.00.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.09% of the stock is owned by company insiders.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.